Kainova Therapeutics

Kainova Therapeutics Expands Phase I/II Trial of DT-7012, a Treg-depleting Anti-CCR8 Antibody, with First Patient Dosed in Europe

First patient dosed in France, expanding the DOMISOL study beyond Australia DT 7012 is being evaluated as monotherapy and in combination with pembrolizumab in a global clinical development program. 9 April 2026 -- Montreal, Canada, Strasbourg, France and Massachusetts, US -- Kainova Therapeutics, a key player for breakthrough treatments in immuno-oncology and inflammation, today announced...

Kainova Therapeutics Announces Positive Phase I Results for DT-9081, an Oral EP4 Receptor Antagonist, in Advanced Solid Tumors

Phase I results demonstrate favorable safety, sustained target engagement, and early signs of anti-tumor activity Reinforce EP4 receptor antagonism as a validated, high-value strategy to overcome immunotherapy resistance. 10 March 2026 -- Montreal, Canada; Strasbourg, France; and Massachusetts, US -- Kainova Therapeutics, a key player for breakthrough treatments in immuno-oncology and inflammation, today announced positive...

Kainova Therapeutics Secures $32M CAD to Accelerate Development of Immuno-Oncology and Inflammation Therapies

Financing led by Investissement Québec with continued support from long-standing investors Plans include the acceleration of clinical development of breakthrough GPCR targeting treatments for patients. 10 February 2026 -- Montreal, Canada; Strasbourg, France; and Massachusetts, US -- Kainova Therapeutics, a key player for breakthrough treatments for patients in immuno-oncology and inflammation, today announced the successful...
7171 Frederick Banting Montreal, QC H4S 1Z9 Canada